NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data
Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately sharpened the stock’s risk reward profile.
See our latest analysis for Relay Therapeutics.
The zovegalisib update lands after a sharp rebound in sentiment, with a roughly 97 percent 90 day share price return and a 104 percent one year total shareholder return, even though the five year total...